Claudia de la Riva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Claudia de la Riva has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Noemí del Castillo
Deparment of Oncology, Universidad Alfonso X el Sabio (UAX), Avenida de la Universidad 1, Villanueva de la Cañada, 28691 Madrid, Spain
2 shared publications - Ana Judith Perisé-Barrios
Unidad de Investigación Biomédica (UIB-UAX), Universidad Alfonso X el Sabio, Madrid, Spain
1 shared publication - Beatriz Davinia Tomeo-Martín
Biomedical Research Unit (UIB-UAX), Universidad Alfonso X el Sabio, Madrid, Spain
1 shared publication - Clara Martín-Carrasco
Small Animal Surgery Service, Hospital Clínico Veterinario, Universidad Alfonso X el Sabio, 28691 Madrid, Spain
1 shared publication - Cristina García
Deparment of Oncology, Universidad Alfonso X el Sabio (UAX), Avenida de la Universidad 1, Villanueva de la Cañada, 28691 Madrid, Spain
1 shared publication - Elisabetta De Angelis
Deparment of Oncology, Universidad Alfonso X el Sabio (UAX), Avenida de la Universidad 1, Villanueva de la Cañada, 28691 Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 2 November 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (11) , 1053
Doxorubicin–Cyclophosphamide Protocol in Dogs with Splenic Haemangiosarcoma and Haemoabdomen: A Retrospective Case Series
This retrospective case series describes 21 dogs with stage II splenic haemangiosarcoma (HSA) and spontaneous haemoabdomen treated with splenectomy followed by a doxorubicin–cyclophosphamide protocol. Median overall survival was 92 days, with longer survival observed in dogs completing three or more chemotherapy cycles. The regimen was well tolerated, with low haematological and gastrointestinal toxicity. Maintenance metronomic chemotherapy was administered in a small subset, and it was associated with prolonged survival. While the sample size is modest, the homogeneous and clinically specific cohort provides hypothesis-generating observations on feasibility, tolerability, and time-aware associations that warrant cautious interpretation and prospective confirmation. No clinical or laboratory variable at diagnosis was independently associated with outcome. While limited by retrospective design and small sample size, this study provides focused data on a specific clinical presentation and supports the feasibility of structured adjuvant treatment in dogs with splenic HSA and haemoabdomen.
- 2 November 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (11) , 1053
Open AccessDoxorubicin–Cyclophosphamide Protocol in Dogs with Splenic Haemangiosarcoma and Haemoabdomen: A Retrospective Case Series
This retrospective case series describes 21 dogs with stage II splenic haemangiosarcoma (HSA) and spontaneous haemoabdomen treated with splenectomy followed by a doxorubicin–cyclophosphamide protocol. Median overall survival was 92 days, with longer survival observed in dogs completing three or more chemotherapy cycles. The regimen was well tolerated, with low haematological and gastrointestinal toxicity. Maintenance metronomic chemotherapy was administered in a small subset, and it was associated with prolonged survival. While the sample size is modest, the homogeneous and clinically specific cohort provides hypothesis-generating observations on feasibility, tolerability, and time-aware associations that warrant cautious interpretation and prospective confirmation. No clinical or laboratory variable at diagnosis was independently associated with outcome. While limited by retrospective design and small sample size, this study provides focused data on a specific clinical presentation and supports the feasibility of structured adjuvant treatment in dogs with splenic HSA and haemoabdomen.
- Open Access
- 28 June 2022
- Published by MDPI AG in Veterinary Sciences
- Vol. 9 (7) , 327
Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients
The use of oncolytic viruses is an innovative approach to lyse tumor cells and induce antitumor immune responses. Eight dogs diagnosed with carcinoma/adenocarcinoma were intratumorally treated with ICOCAV15, an oncolytic canine adenovirus (CAV). To evaluate the treatment’s safety, a blood count, biochemistry, and coagulation test were performed before treatment and during follow-up. Immune populations were analyzed by flow cytometry. Anti-adenovirus antibodies were also determined. The immune infiltration, vascularization, and viral presence in the tumor were determined by CD3, CD4, CD20, CD31 and CAV by immunohistochemistry. All the dogs maintained a good quality of life during follow-up, and some had increased median survival time when compared with dogs treated with chemotherapy. No treatment-related adverse effects were detected. The Response Evaluation Criteria In Solid Tumors criteria were also assessed: two patients showed a partial response and the rest showed stable disease at various times during the study. ICOCAV15 was detected inside the tumor during follow-up, and antiviral antibodies were detected in all patients. Furthermore, the tumor-infiltrating immune cells increased after viral administration. Therefore, we suggest that intratumorally administered ICOCAV15 could represent as a new tool for the treatment of canine carcinoma because it is safe, well-tolerated by dogs, and shows promising results.
- 28 June 2022
- Published by MDPI AG in Veterinary Sciences
- Vol. 9 (7) , 327
Open AccessSafety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients
The use of oncolytic viruses is an innovative approach to lyse tumor cells and induce antitumor immune responses. Eight dogs diagnosed with carcinoma/adenocarcinoma were intratumorally treated with ICOCAV15, an oncolytic canine adenovirus (CAV). To evaluate the treatment’s safety, a blood count, biochemistry, and coagulation test were performed before treatment and during follow-up. Immune populations were analyzed by flow cytometry. Anti-adenovirus antibodies were also determined. The immune infiltration, vascularization, and viral presence in the tumor were determined by CD3, CD4, CD20, CD31 and CAV by immunohistochemistry. All the dogs maintained a good quality of life during follow-up, and some had increased median survival time when compared with dogs treated with chemotherapy. No treatment-related adverse effects were detected. The Response Evaluation Criteria In Solid Tumors criteria were also assessed: two patients showed a partial response and the rest showed stable disease at various times during the study. ICOCAV15 was detected inside the tumor during follow-up, and antiviral antibodies were detected in all patients. Furthermore, the tumor-infiltrating immune cells increased after viral administration. Therefore, we suggest that intratumorally administered ICOCAV15 could represent as a new tool for the treatment of canine carcinoma because it is safe, well-tolerated by dogs, and shows promising results.